Olmesartan Ip/bp/usp Medicine Raw Materials

Niksan Pharmaceuticalis one of the leading manufacturer, supplier and exporter of the Olmesartan. The best product manufactured by Niksan Pharmaceutical is Olmesartan. We manufacture, supply and export best quality product of Olmesartan API along with Olmesartan formulations.
Niksan Pharmaceutical provides best quality product of Olmesartan in all states of India like Kerala, Punjab, Rajasthan, Telangana, Uttar Pradesh, Gujarat, Delhi, Tamil Nadu, Bihar, Karnataka, Jammu and Kashmir, Maharashtra, West Bengal, Odisha, Madhya Pradesh, Andhra Pradesh, Haryana and many other states.
Niksan Pharmaceutical is also manufacture and exports large quantity of Olmesartan products in whole globe since many years in countries like Guatemala, Venezuela, Honduras, Bangladesh, Nicaragua, Ireland, El Salvador, Italy, United States , Australia, Dominican Republic, Mexico, Portugal, Canada, Chile, South Korea, Spain, United Arab Emirates, Philippines and many more countries.
Olmesartanbelongs to the medicine class called angiotensin receptor blockers. Olmesartan used in the treatment of hypertension. Olmesartan decrease the high blood pressure by relaxing the smooth muscle by vasodilation.
IUPAC NAME:4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(1H-1, 2,3,4-tetrazol-5-yl) phenyl] phenyl} methyl)-1H-imidazole-5-carboxylic acid
CAS NO: 144689-24-7
FORMULA:C24H26N6O3

MOLECULAR MASS:446.50 g/mol

STORAGE CONDITIONS:Store medicine in cool and dry place, away from direct heat and sunlight.Do not store medicine in humid place like bathroom or kitchen.Keep away from children and pets.

HOW TO USE:Take medicine once per day by mouth.If you are using the oral liquid form, shake the container before use.Carefully measure the liquid dosage form.

HOW OLMESARTAN WORKS:Olmesartan inhibits the high blood pressure by binding with angiotensin II receptor. Angiotensin II cause vasoconstriction so by inhibiting the enzyme Olmesartan cause vasodilation of the smooth muscle and by this blood flow increases and prevents hypertension.

PHARMACOKINETICS:Olmesartan rapidly absorbed IN GI track after the oral administration with the bioavaibility of 4.5% to 28.6%.Almost 99% of Olmesartan binds with the blood plasma albumin.The half-life of Olmesartan is 10-15hours.Approximately 10-16% of Olmesartan eliminated through urine.

SIDE EFFECTS:Common side effects of Olmesartan are lightheadness and dizziness.Other side effects like fainting, high potassium blood level, signs of kidney problem.Some other rare reactions like skin rash, itching, swelling of skin, dizziness, trouble in breathing.

PRECAUTIONS:Before talking the Olmesartan medicine, tell your doctor if you are allergic to Olmesartan.Tell your doctor about your medical history like liver disease, kidney disease, dehydration or any respiratory problem.This medicine makes you dizzy so kindly avoid taking alcohol and cannabis products.Also avoid driving or operating machineries because Olmesartan makes you dizzy.

CDSCO APPROVAL:FDC of Olmesartan Medoxomil (20mg/40mg/40mg) + Hydrochlorthiazide (12.5mg/12.5mg/25mg)approved by CDSCO in India in 02.12.2005,
Amlodipine Besilate IP eq.to Amlodipine 10mg/5mg/5mg/5mg/2.5mg + Olmesartan Medoxomil 40mg/40mg/20mg/5mg/5mg + Hydrochlorothiazide IP 25mg/12.5mg/12.5mg/12.5mg/12.5mg Tablet 23.11.2011
Olmesartan Medoxomil (20mg) + Amlodipine Besylate (5mg) Tablet approved by CDSCO in India in 15.10.2007,
Metoprolol succinate ER 25mg+50mg + Olmesartan 20/20mg approved by CDSCO in India in 19.07.2010,
Olmesartan 40mg + Amlodipine 5mg (Additional Strength) approved by CDSCO in India in 09.08.2010,
Olmesartan medoximil-20mg + Ramipril-5mg. Tablet approved by CDSCO in India in 12.6.2007,
Olmesartan (20/40mg) + Atorvastatin 5/10/20mg film coated tablets approved by CDSCO in India in 27.10.2009,
Olmesartan + Ramipril (40mg + 5mg) tablets (Additional Strength) approved by CDSCO in India in 15.09.2008,
Olmesartan (as Medoxomil) 10mg (addl. Strength) approved by CDSCO in India in 18.05.2006,
Olmesartan Medoxomil (5mg/20mg/40mg) Tablet approved by CDSCO in India in 21.07.2005,
Olmesartan 40mg + Hydrochlorthiazide 25mg tablet (addl. Strength) approved by CDSCO in India in 28.06.2006.

FORMULATIONS AVAILABLE IN MARKET:
Olmesartan Medoxomil 5mg tablets
Olmesartan Medoxomil20mg tablets
Olmesartan Medoxomil 40mg tablets
Olmesartan Medoxomil 10mg tablets
Olmesartan Medoxomil 20mg + amlodipine 5mg tablets
Metoprolol succinate ER 25mg+ Olmesartan 20mg tablets
Metoprolol succinate ER 50mg + Olmesartan 20mg tablets
Olmesartan + Ramipril (40mg + 5mg) tablets
Olmesartan 40mg + Hydrochlorthiazide 25mg tablets
Olmesartan 40mg + Amlodipine 5mg tablets

Note: Product protected by valid patents are not offered for sale in countries where such patents are still valid and its liability is at Buyers Risk.

REFERENCES:

www.webmd.com
https://pubchem.ncbi.nlm.nih.gov
https://go.drugbank.com
https://cdscoonline.gov.in
https://www.wikipedia.org/
https://www.drugs.com
https://www.zaubacorp.com
https://www.practo.com/consult